MRVI SEC-arkiveringer - Maravai LifeSciences Holdings, Inc.- Årsrapport, Fullmaktsdokument, Prospekt

Grunnleggende statistikk

LEI	549300BD2BYCE9IZ0C48
CIK	1823239

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Maravai LifeSciences Holdings, Inc.

SEC Filings (Chronological Order)

På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.

August 11, 2025	EX-10.6	and Restricted Stock Unit Agreement (2025 RSU Award Agreement - Chairman of Exhibit 10.6 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”
August 11, 2025	EX-99.1	MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which exclu Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS Announced organizational restructuring and operating cost reduction initiatives targeting more than $50 million in annualized cost savings Quarterly base business revenue, which excludes revenue from high-volume CleanCap® for commercialized vaccine programs, grew 5% year-over-year Net Loss Reduction, Positive Adjusted
August 11, 2025	EX-10.4	orm of Stock Option Grant Notice and Stock Option Agreement (2025 Executive New Hire Grant) Exhibit 10.4 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN STOCK OPTION GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) the sto
August 11, 2025	EX-10.3	Notice and Restricted Stock Unit Agreement (2025 Executive New Hi Exhibit 10.3 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”
August 11, 2025	EX-10.5	orm of Performance Stock Unit Grant Notice and Performance Stock Unit Agreement (2025 Exhibit 10.5 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN PERFORMANCE STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant
August 11, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39725 Mar
August 11, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Maravai LifeScienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)
August 11, 2025	EX-10.7	cted Stock Unit Grant Notice and Restricted S Exhibit 10.7 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”
July 18, 2025	EX-16.1	Letter of Ernst & Young LLP to the Securities and Exchange Commission, dated July Exhibit 16.1 July 18, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated July 18, 2025, of Maravai LifeSciences Holdings, Inc. and are in agreement with the statements contained in the second sentence in the first paragraph and the second, third, fourth and fifth paragraphs on page 1 therein. We have no basis to a
July 18, 2025	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (
June 25, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (
June 25, 2025	EX-10.1	Employment Agreement, effective as of June 30, 2025, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Rajesh Asarpota. Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of June 25, 2025 and effective as of the Effective Date (as defined below), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Rajesh Asarpota (“Executive”). Capitali
June 25, 2025	EX-99.1	Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer Exhibit 99.1 Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer SAN DIEGO, Calif., June 25, 2025 — Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh “Raj” Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effe
June 9, 2025	EX-10.1	Employment Agreement of Bernd Brust, effective as of June 8, 2025, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Bernd Brust. EX-10.1 Exhibit 10.1 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of June 8, 2025 and effective as of the Effective Date (as defined below), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Bernd Brust (“Executive”). Capit
June 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2025 Maravai LifeSciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C
June 9, 2025	EX-99.1	Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors EX-99.1 Exhibit 99.1 Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors SAN DIEGO, Calif., June 9, 2025 — Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member
May 28, 2025	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 22, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C
May 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39725 Ma
May 12, 2025	EX-FILING FEES	Filing Fee Table. Exhibit 107 FEE TABLES FOR FORM S-8 Calculation of Filing Fee Tables Form S-8 (Form Type) Maravai LifeSciences Holdings, Inc.
May 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Maravai LifeSciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C
May 12, 2025	S-8	As filed with the Securities and Exchange Commission on May 12, 2025 As filed with the Securities and Exchange Commission on May 12, 2025 Registration No.
May 12, 2025	EX-99.1	MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS SAN DIEGO, Calif., — May 12, 2025 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Hig
April 18, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
March 20, 2025	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)
March 18, 2025	EX-10.42	Separation Agreement and General Release of Claims by and between TriLink Biotechnologies, LLC, and Andrew Burch, dated as of January 17, 2025. Exhibit 10.42 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS This Confidential Separation Agreement and General Release of Claims (this “Agreement” or “Release”) is entered into between Drew Burch (“you”) and TriLink BioTechnologies, LLC (the “Company”). You and the Company (together, the “Parties”) agree as follows: Termination of Employment Relationship: Your employment relation
March 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Maravai LifeScienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)
March 18, 2025	EX-21.1	List of subsidiaries of Maravai LifeSciences Holdings, Inc. Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC Alphazyme, LLC (Delaware) Cygnus Technologies, LLC (Delaware) Maravai LifeSciences International Holdings, Inc. (Delaware) M
March 18, 2025	EX-99.1	MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Schedules Conference Call for Thursday, March 20, 2025 Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Schedules Conference Call for Thursday, March 20, 2025 SAN DIEGO, Calif., — March 18, 2025 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter
March 18, 2025	EX-19.1	nsider Trading Policy Amended and Restated effective as of November 15, 2024 AMENDED AND RESTATED INSIDER TRADING POLICY MARAVAI LIFESCIENCES HOLDINGS, INC.
March 18, 2025	EX-4.2	Description of Maravai LifeSciences Holdings, Inc.’s Securities. Exhibit 4.2 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2024, Maravai LifeSciences Holdings, Inc. (the “Company,” “we,” “our,” and “us”) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. T
March 18, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact
March 4, 2025	NT 10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER 001-39725 CUSIP NUMBER 56600D107 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tra
February 25, 2025	EX-99.1	MARAVAI LIFESCIENCES POSTPONES ITS FOURTH QUARTER AND FULL YEAR 2024 EARNINGS RELEASE AND CONFERENCE CALL Exhibit 99.1 MARAVAI LIFESCIENCES POSTPONES ITS FOURTH QUARTER AND FULL YEAR 2024 EARNINGS RELEASE AND CONFERENCE CALL SAN DIEGO, Calif., — February 25, 2025 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that it is postponing its previously announced earnings release and
February 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Maravai LifeSci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio
February 19, 2025	CORRESP	Maravai LifeSciences Holdings, Inc. February 19, 2025 Maravai LifeSciences Holdings, Inc. February 19, 2025 Via EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Christine Torney, Kevin Vaughn Re: Maravai LifeSciences Holdings, Inc. Form 10-K for the Year Ended December 31, 2023 File No. 001-39725 Ladies and Gentlemen: We are writing to respond to the c
January 8, 2025	EX-99.1	Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue Announces Earnings Release Date Maravai LifeSciences Announces Preliminary Unaudited 2024 Revenue Announces Earnings Release Date SAN DIEGO, CA – January 8, 2025 - Maravai LifeSciences Holdings, Inc.
January 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 Maravai LifeScien UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)
December 18, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 Maravai LifeSci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio
December 5, 2024	EX-10.1	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (2024 RSU Award). 2024RSUAE MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) t
December 5, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation
December 5, 2024	EX-10.2	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (202 2025RSUAE MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) t
December 5, 2024	EX-99.1	Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors Carl Hull to Retire as Executive Chairman Exhibit 99.1 Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors Carl Hull to Retire as Executive Chairman SAN DIEGO, Calif.; – December 5, 2024 - Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from hi
November 14, 2024	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. / Point72 Asset Management, L.P. - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment SC 13G/A 1 p24-3157sc13ga.htm MARAVAI LIFESCIENCES HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D107 (CUSIP Number) September 30, 2024 (Date of Event Which Req
November 13, 2024	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. / MARAVAI LIFE SCIENCES HOLDINGS 2, LLC - SC 13G/A Passive Investment SC 13G/A 1 d873306dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D 107 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing o
November 13, 2024	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. / 12 West Capital Management LP - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment SC 13G/A 1 p24-3081sc13ga.htm MARAVAI LIFESCIENCES HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D107 (CUSIP Number) September 30, 2024 (Date of Event Which Req
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-3972
November 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation
November 7, 2024	EX-99.1	MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS Announces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D SAN DIEGO, Calif., — November 7, 2024 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,
October 29, 2024	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 MRVISC13GA1Oct2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MARAVAI LIFESCIENCES HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 56600D107 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this
September 12, 2024	EX-10.1	Third Amendment to Credit Agreement, dated September 10, 2024, among Maravai Intermediate Holdings, LLC, Cygnus Technologies, LLC, TriLink Biotechnologies, LLC, Maravai Topco Holdings, LLC, Morgan Stanley Senior Funding, Inc. and the other lenders and parties thereto. Execution Version THIRD AMENDMENT TO CREDIT AGREEMENT This THIRD AMENDMENT TO CREDIT AGREEMENT, dated as of September 10, 2024 (this “Amendment”), shall, on, and subject to the occurrence of, the Revolver Extension and Amendment Date (as defined below), amend that certain Credit Agreement, dated as of October 19, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified
September 12, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporati
August 16, 2024	CORRESP	MARAVAI LIFESCIENCES HOLDINGS, INC. August 16, 2024 MARAVAI LIFESCIENCES HOLDINGS, INC. August 16, 2024 Via EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3628 Attention: Christine Torney Kevin Vaughn Re: MARAVAI LIFESCIENCES HOLDINGS, INC. Form 10-K for the Year Ended December 31, 2023 File No. 001-39725 Ladies and Gentlemen: We write in response to commen
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39725 Mar
August 7, 2024	EX-99.1	MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — August 7, 2024 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results
August 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)
July 29, 2024	EX-99.1	Maravai LifeSciences Appoints Trey Martin to Board of Directors Maravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experience Exhibit 99.1 Maravai LifeSciences Appoints Trey Martin to Board of Directors Maravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experience SAN DIEGO, July 29, 2024 - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators,
July 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 Maravai LifeScience UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (
June 24, 2024	CORRESP	MARAVAI LIFESCIENCES HOLDINGS, INC. June 25, 2024 MARAVAI LIFESCIENCES HOLDINGS, INC. June 25, 2024 Via EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3628 Attention: Christine Torney Kevin Vaughn Re: MARAVAI LIFESCIENCES HOLDINGS, INC. Form 10-K For the Year Ended December 31, 2023 File No. 001-39725 Ladies and Gentlemen: On behalf of Maravai LifeSciences
June 12, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (
June 10, 2024	EX-99	JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn
June 10, 2024	SC 13G	MRVI / Maravai LifeSciences Holdings, Inc. / Point72 Asset Management, L.P. - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D107 (CUSIP Number) June 7, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
May 28, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C
May 14, 2024	SC 13G	MRVI / Maravai LifeSciences Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MARAVAI LIFESCIENCES HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 56600D107 (CUSIP Number) MAY 9, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39725 Ma
May 9, 2024	EX-10.1	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (January 2024) (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.’s Form 10-Q filed on May 9, 2024). Exhibit 10.1 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”
May 9, 2024	EX-10.2	ment Agreement of Andrew Burch, effective as of February 25, 2024, among Maravai LifeSciences Holdings, Inc., TriLink Biotechnologies, LLC and And Exhibit 10.2 SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS SECOND AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of February 25, 2024 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), TriLink Biotechnologies, LLC, a Delaware limited liability company (“Employer”), and Andrew Burch (“Executive”). Capita
May 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (Co
May 8, 2024	EX-99.1	MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS Continued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — May 8, 2024 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for
April 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e
February 29, 2024	EX-10.15	between 10240 Flanders Investors LL Exhibit 10.15 LEASE AGREEMENT BETWEEN 10240 FLANDERS INVESTORS LLC, a Delaware limited liability company (LANDLORD) AND TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (TENANT) August 6, 2021 10240-10247 FLANDERS COURT SAN DIEGO, CALIFORNIA TABLE OF CONTENTS Page The table of contents is empty. Heading styles must be applied in the document and be selected in the table of conten
February 29, 2024	EX-10.24	Amendment No.1, effective as of July 27, 2023, to the Amended and Restated Employment Agreement of Carl W. Hull, dated May 8, 2023, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Carl W. Hull (incorporated by reference to Exhibit 10.24 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 29, 2024). Exhibit 10.24 AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”), entered into on July 27, 2023 (the “Effective Date”), is by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W
February 29, 2024	EX-10.17	Second Amendment to Lease Agreement, dated October 1, 2022, by and between 10240 Flanders Investors LLC and Tri Exhibit 10.17 SECOND AMENDMENT TO LEASE AGREEMENT This SECOND AMENDMENT TO LEASE AGREEMENT (“Amendment”) is entered into as of October 1, 2022 (“Effective Date”), by and between 10240 FLANDERS INVESTORS LLC, a Delaware limited liability company (“Landlord”), and TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“Tenant”), with reference to the facts set forth in the Recitals belo
February 29, 2024	EX-10.35	Form of Performance Stock Unit Grant Notice and Performance Stock Unit Agreement Exhibit 10.35 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN PERFORMANCE STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participan
February 29, 2024	EX-10.21	ment to Credit Agreement to Credit Agreement, dated as of Augu Exhibit 10.21 EXECUTION VERSION FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is dated as of August 11, 2021 and is entered into by and among MARAVAI INTERMEDIATE HOLDINGS, LLC, a Delaware limited liability company (“Parent Borrower”), and MORGAN STANLEY SENIOR FUNDING, INC. (“MS”), as administrative agent for the Lenders (in such capacity, the “Ad
February 29, 2024	EX-10.16	First Amendment to Lease Agreement, dated October 14, 2021, by and between 10240 Flanders Investors LLC and Tri Exhibit 10.16 FIRST AMENDMENT TO LEASE AGREEMENT This FIRST AMENDMENT TO LEASE AGREEMENT (“Amendment”) is entered into as of October 14, 2021 (“Effective Date”), by and between 10240 FLANDERS fNVESTORS LLC, a Delaware limited liability company (“Landlord”), and TRILINK BIOTECHNOLOGIES, LLC, a Delaware limited liability company (“Tenant”), with reference to the facts set forth in the Recitals below
February 29, 2024	EX-97.1	Clawback Policy of Maravai LifeSciences Holdings, Inc. (incorporated by reference to Exhibit 97.1 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 29, 2024). Exhibit 97.1 Effective October 2, 2023 CLAWBACK POLICY MARAVAI LIFESCIENCES HOLDINGS, INC. PURPOSE Maravai LifeSciences Holdings, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The Company’s
February 29, 2024	EX-21.1	List of subsidiaries of Maravai LifeSciences Holdings, Inc. Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC Alphazyme, LLC (Delaware) Cygnus Technologies, LLC (Delaware) Maravai LifeSciences International Holdings, Inc. (Delaware) M
February 29, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact
February 29, 2024	EX-10.33	(incorporated by reference to Exhibit 10.33 to Maravai LifeSciences Holdings, Inc. Exhibit 10.33 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN STOCK OPTION GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”) the st
February 29, 2024	EX-10.34	ed Stock Unit Grant Notice and Restricted Stock Unit Agreement. Exhibit 10.34 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant
February 29, 2024	EX-10.18	d as of June 11, 2021, by and between Exhibit 10.18 LEASE AGREEMENT BETWEEN CIGG, LLC Landlord AND CYGNUS TECHNOLOGIES, LLC Tenant DATED: June 11, 2021 1 LEASE THIS LEASE (this “Lease”) is entered into this June 11, 2021 (the date of execution of this Lease by authorized parties of Landlord and Tenant shall be the “Effective Date”), by and between CIGG, LLC, a North Carolina limited liability company, having its principal place of bus
February 29, 2024	EX-4.2	Description of Maravai LifeSciences Holdings, Inc.’s Securities. Exhibit 4.2 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2023, Maravai LifeSciences Holdings, Inc. (the “Company,” “we,” “our,” and “us”) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. T
February 28, 2024	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. / 12 West Capital Management LP - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment SC 13G/A 1 p24-1054sc13ga.htm MARAVAI LIFESCIENCES HOLDINGS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2023** (Date of Event Which Re
February 28, 2024	EX-99	JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 exhibit99.htm JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without
February 22, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio
February 22, 2024	EX-99.1	MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation EX-99.1 2 exhibit991-q42023.htm EX-99.1 Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Innovation SAN DIEGO, Calif., — February 22, 2024 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech
February 13, 2024	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01397-maravailifesciencesh.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Maravai Lifesciences Holdings, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 56600D107 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check th
February 8, 2024	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. / MARAVAI LIFE SCIENCES HOLDINGS 2, LLC - SC 13G/A Passive Investment SC 13G/A 1 d63977dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D 107 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of
January 5, 2024	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) MARAVAI LIFESCIENCES HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 56600D107 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropriate bo
November 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, In
November 7, 2023	EX-99.1	MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innov Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS Announces Realignment to Drive Operational Efficiencies and Streamline the Business Post-Pandemic Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — November 7, 2023 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life sci
November 7, 2023	SC 13G/A	MRVI / Maravai LifeSciences Holdings Inc - Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) October 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appro
November 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation
October 26, 2023	SC 13G	MRVI / Maravai LifeSciences Holdings Inc - Class A / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 MRVISC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MARAVAI LIFESCIENCES HOLDINGS, INC. (Name of Issuer) CLASS A COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 56600D107 (CUSIP Number) OCTOBER 20, 2023 (Date of event which requires filing of this statement) Check the appropriat
August 8, 2023	EX-10.2	Form of Amendment No. 1 to Stock Option Grant Notice. EXHIBIT 10.2 AMENDMENT NO. 1 TO STOCK OPTION GRANT NOTICE This AMENDMENT NO. 1 TO STOCK OPTION GRANT NOTICE (this “Amendment”) is entered into effective as of [], 2023 (the “Amendment Effective Date”), by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”) and [] (“Participant”). Capitalized terms used but not defined herein shall have the meanings ascribed to s
August 8, 2023	EX-10.1	Form of Amendment No. 1 to Restricted Stock Unit Grant Notice. EXHIBIT 10.1 AMENDMENT NO. 1 TO RESTRICTED STOCK UNIT GRANT NOTICE This AMENDMENT NO. 1 TO RESTRICTED STOCK UNIT GRANT NOTICE (this “Amendment”) is entered into effective as of [], 2023 (the “Amendment Effective Date”), by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”) and [] (“Participant”). Capitalized terms used but not defined herein shall have the mean
August 8, 2023	EX-10.3	Amendment No. 1 to Performance Stock Unit Grant Notice by and between EXHIBIT 10.3 AMENDMENT NO. 1 TO PERFORMANCE STOCK UNIT GRANT NOTICE This AMENDMENT NO. 1 TO PERFORMANCE STOCK UNIT GRANT NOTICE (this “Amendment”) is entered into effective as of July 6, 2023 (the “Amendment Effective Date”), by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”) and William E. Martin, III (“Participant”). Capitalized terms used but not defined
August 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (E
August 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Maravai LifeScienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)
August 7, 2023	EX-99.1	MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — August 7, 2023 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results
July 27, 2023	EX-99.1	Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition William “Trey” Martin, III assumes the role of Maravai’s CEO Carl Hull to continue to serve as Executive Chairman Exhibit 99.1 Maravai LifeSciences Announces Completion of Planned CEO Leadership Transition William “Trey” Martin, III assumes the role of Maravai’s CEO Carl Hull to continue to serve as Executive Chairman SAN DIEGO, Calif.; – July 27, 2023 - Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and b
July 27, 2023	EX-10.1	Amendment No. 1, effective as of July 27, 2023, to the Amended and Restated Employment Agreement of Carl W. Hull, dated as of May 8, 2023, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate holdings, LLC and Carl W. Hull. EXHIBIT 10.1 AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”), entered into on July 27, 2023 (the “Effective Date”), is by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W.
July 27, 2023	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (
July 20, 2023	EX-99.1	Maravai LifeSciences Announces Appointment of New Director to the Board Exhibit 99.1 Maravai LifeSciences Announces Appointment of New Director to the Board SAN DIEGO – July 20, 2023 - Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Robert (“Chip”) Hance has stepped down from the Company’s Board of Directors (the “Board”) effec
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 Maravai LifeScience UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 19, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (
May 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Maravai LifeSciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C
May 9, 2023	EX-10.3	8, 2023, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and William Exhibit 10.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 8, 2023 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and William “Trey” Martin, III (“Executive”). Capita
May 9, 2023	EX-10.1	Employment Agreement by and among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC, and Peter M. Leddy Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is signed as of June 21, 2022, and effective as of June 27, 2022 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Peter M. Leddy (“Executive”). Capitalized terms used but
May 9, 2023	EX-10.6	Amended and Restated Employment Agreement of Christine Dolan, dated as of May 8, 2023 among Maravai LifeSciences Holdings, Inc., Cygnus Technologies, LLC, MLSC Holdings, LLC and Christine Dolan (incorporated by reference to Exhibit 10.6 to Maravai LifeSciences Holdings, Inc.’s Form 10-Q filed on May 9, 2023). Exhibit 10.6 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 8, 2023 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Cygnus Technologies, LLC, a Delaware limited liability company (“Employer”), MLSC Holdings, LLC, a Delaware limited liability company (“MLS
May 9, 2023	EX-10.5	Amended and Restated Employment Agreement by and among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Peter M. Leddy, Ph.D., dated as of May 8, 2023. Exhibit 10.5 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 8, 2023 (the “Effective Date”), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Peter M. Leddy, Ph.D. (“Executive”). Capitalized
May 9, 2023	EX-10.4	Amended and Restated Employment Agreement of Kevin Herde, dated May 8, 2023, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Kevin Herde (incorporated by reference to Exhibit 10.4 to Maravai LifeSciences Holdings, Inc.’s Form 10-Q filed on May 9, 2023). Exhibit 10.4 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is made as of May 8, 2023, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Kevin Herde (“Executive”). Capitalized terms used but not otherwise defined
May 9, 2023	EX-10.2	Amended and Restated Employment Agreement by and among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Carl W. Hull, dated as of May 8, 2023. Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”) is effective as of May 8, 2023, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W. Hull (“Executive”). Capitalized terms used but not otherwise de
May 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (
May 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Maravai LifeSciences UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (Co
May 8, 2023	EX-99.1	MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS Continued Focus on Expanding Product Portfolio, Market Leadership and Scientific Innovation SAN DIEGO, Calif., — May 8, 2023 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for
April 20, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( as permitted by Rule 14a-6(
March 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Maravai LifeScience UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Maravai LifeScienc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)
February 28, 2023	EX-4.2	Description of Maravai LifeSciences Holdings, Inc.’s Securities. Exhibit 4.2 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2022, Maravai LifeSciences Holdings, Inc. (the “Company,” “we,” “our,” and “us”) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. T
February 28, 2023	EX-21.1	List of subsidiaries of Maravai LifeSciences Holdings, Inc. Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Alphazyme, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC TriLink Biotechnologies, LLC (Delaware) Glen Research, LLC (Delaware) MockV Solutions, Inc. (Maryl
February 28, 2023	EX-10.4	Form of Senior Management Agreement - Capital Units and Incentive Units (incorporated by reference to Exhibit 10.4 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 28, 2023). EXHIBIT 10.4 FORM OF SENIOR MANAGEMENT AGREEMENT (CAPITAL UNITS AND INCENTIVE UNITS) THIS SENIOR MANAGEMENT AGREEMENT (this “Agreement”) is made as of [●], by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), [Maravai Life Sciences, Inc.], a Delaware corporation (“Employer”), and [●] (“Executive”). Capitalized terms used but not otherwise defined
February 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact
February 28, 2023	EX-10.6	Form of Amendment to Senior Management Agreement (incorporated by reference to Exhibit 10.6 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 28, 2023). EXHIBIT 10.6 FORM OF AMENDMENT TO SENIOR MANAGEMENT AGREEMENT THIS AMENDMENT TO THE SENIOR MANAGEMENT AGREEMENT (this “Amendment”), effective as of [●], is made by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), [●]1 (“Employer”), [●] (“Executive”), GTCR Fund XI/B LP, a Delaware limited partnership (“Fund XI/B”), GTCR/Maravai Splitter LP, a Dela
February 28, 2023	EX-10.5	Form of Senior Management Agreement - Incentive Units (incorporated by reference to Exhibit 10.5 to Maravai LifeSciences Holdings, Inc.’s Form 10-K filed on February 28, 2023). EXHIBIT 10.5 FORM OF SENIOR MANAGEMENT AGREEMENT (INCENTIVE UNITS) THIS SENIOR MANAGEMENT AGREEMENT (this “Agreement”) is made as of [●], by and among Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (the “Company”), [●]1 (“Employer”), and [●] (“Executive”). Capitalized terms used but not otherwise defined herein shall have the meanings set forth in Section 8 of this Agree
February 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Maravai LifeSci UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio
February 22, 2023	EX-99.1	MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Base business revenues, excluding COVID-19 related CleanCap® revenues, were up 67% in the fourth quarter and up 17% for the full year Announces acquisition of privately- Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS Base business revenues, excluding COVID-19 related CleanCap® revenues, were up 67% in the fourth quarter and up 17% for the full year Announces acquisition of privately-held Alphazyme, LLC, adding critical enzyme manufacturing capabilities to Maravai’s Nucleic Acid Production Segment SAN DIEGO, Calif., —
February 14, 2023	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / Select Equity Group, L.P. - SCHEDULE 13G/A, AMENDMENT #3 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic
February 14, 2023	EX-99.1	EXHIBIT 99.1 EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
February 9, 2023	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01363-maravailifesciencesh.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Maravai LifeSciences Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 56600D107 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the
February 8, 2023	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
December 1, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Maravai LifeScie UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2022 Maravai LifeSciences Holdings, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-39725 85-2786970 (State or Other Jurisdiction of Incorporation) (C
December 1, 2022	EX-99.1	Maravai LifeSciences Announces Updated CEO Leadership Transition Plans Maravai announces plans for William “Trey” Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Marav Exhibit 99.1 Maravai LifeSciences Announces Updated CEO Leadership Transition Plans Maravai announces plans for William ?Trey? Martin, III to serve as President of its Biologics Safety Testing Segment and its expectation that he will then assume the role of Maravai?s CEO in July 2023 Carl Hull to continue to serve as Executive Chairman and Interim CEO SAN DIEGO, Calif.; ? December 1, 2022?Maravai
November 10, 2022	EX-99.1	EXHIBIT 99.1 EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
November 10, 2022	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / Select Equity Group, L.P. - SCHEDULE 13G/A, AMENDMENT #2 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) October 31, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which
November 4, 2022	EX-2.1	Amendment No. 2, dated as of August 30, 2022, to the Agreement and Plan of Merger, dated as of August 5, 2021, among Maravai Life Sciences, LLC (f/k/a Maravai Life Sciences, Inc.), Voyager Group Holdings, Inc., Vector Laboratories, Inc., Maravai LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC (incorporated by reference to Exhibit 2.1 to Maravai LifeSciences Holdings, Inc.’s Form 10-Q filed on November 4, 2022). Exhibit 2.1 AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER (this ?Amendment?), is made as of August 30, 2022, by and among Maravai Life Sciences, LLC, a Delaware limited liability company (f/k/a Maravai Life Sciences, Inc.) (?Seller?), Voyager Group Holdings, Inc., a Delaware corporation (?Parent?), Vector Laboratories, Inc., a California corpo
November 4, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, In
November 2, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation
November 2, 2022	EX-99.1	MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Updates Revenue, Adjusted EBITDA and Adjusted EPS Guidance for 2022 Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS Updates Revenue, Adjusted EBITDA and Adjusted EPS Guidance for 2022 SAN DIEGO, Calif., ? November 2, 2022 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter e
October 19, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation
October 19, 2022	EX-99.1	Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against Suit Exhibit 99.1 Maravai LifeSciences Temporarily Reinstates Carl Hull as CEO Amidst Pending Noncompetition Litigation Maravai LifeSciences and Recently-Appointed CEO Trey Martin Vigorously Defending Against Suit SAN DIEGO, Calif., ? October 19, 2022 ? Executive Chairman and former CEO of Maravai LifeSciences, Inc. (NASDAQ: MRVI) Carl Hull, has been reinstated as CEO of the company on an interim basis
October 3, 2022	EX-10.5	Form of Performance Stock Unit Grant Notice and Performance Stock Unit Agreement (incorporated by reference to Exhibit 10.5 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022). EXHBIT 10.5 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN PERFORMANCE STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the ?Plan?), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the ?Company?), hereby grants to the individual listed below (?Participant?
October 3, 2022	EX-99.1	Maravai LifeSciences Announces CEO Leadership Transition -William “Trey” Martin, III appointed to succeed Carl Hull as Chief Executive Officer - Hull to Serve as Executive Chairman of the Board of Directors Maravai LifeSciences Announces CEO Leadership Transition -William ?Trey? Martin, III appointed to succeed Carl Hull as Chief Executive Officer - Hull to Serve as Executive Chairman of the Board of Directors SAN DIEGO, Calif.
October 3, 2022	EX-10.2	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.2 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022). EXHIBIT 10.2 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the ?Plan?), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the ?Company?), hereby grants to the individual listed below (?Participant?
October 3, 2022	EX-10.3	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.3 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022). EXHIBIT 10.3 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the ?Plan?), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the ?Company?), hereby grants to the individual listed below (?Participant?
October 3, 2022	EX-10.6	Amendment No.1, effective as of September 30, 2022, to the Employment Agreement of Carl W. Hull, dated November 24, 2020, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Carl W. Hull (incorporated by reference to Exhibit 10.6 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022). EXHIBIT 10.6 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?), entered into on September 29, 2022 is by and between Maravai LifeSciences Holdings, Inc., a Delaware corporation (?Parent?), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (?Employer?), and Carl W. Hull (?Executive?). WHEREAS, Executive, Parent and Employer are party
October 3, 2022	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporati
October 3, 2022	EX-10.1	Employment Agreement of William “Trey” Martin, III, effective as of September 30, 2022, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and William “Trey” Martin, III (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on October 3, 2022). EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is signed as of September 29, 2022, and effective as of September 30, 2022 (the ?Effective Date?), by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (?Parent?), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (?Employer?), and William ?Trey? Martin, III (?Executive?). Capi
September 6, 2022	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
September 6, 2022	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) August 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
August 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (E
August 4, 2022	EX-99.1	MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Record First Half Revenue, Net Income, Adjusted EBITDA and EPS Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS Record First Half Revenue, Net Income, Adjusted EBITDA and EPS SAN DIEGO, Calif., ? August 4, 2022 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended
August 4, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)
July 12, 2022	CORRESP	MARAVAI LIFESCIENCES HOLDINGS, INC. July 12, 2022 CORRESP 1 filename1.htm MARAVAI LIFESCIENCES HOLDINGS, INC. July 12, 2022 Via EDGAR Submission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-3628 Attention: Vanessa Robertson Christine Torney Re: MARAVAI LIFESCIENCES HOLDINGS, INC. Form 10-K For the Year Ended December 31, 2021 File No. 001-39725 Ladies and Gentlemen: On be
May 16, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C
May 6, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (
May 6, 2022	EX-10.3	Employment Agreement, dated as of November 24, 2020 among Maravai LifeSciences Holdings, Inc., Vector Laboratories, Inc. and Lisa Sellers. Exhibit 10.3 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (?Parent?), Vector Laboratories, Inc., a California corporation (?Employer?), and Lisa Sellers (?Executive?). Capitalized terms used but not otherwise defined herein shall have the meanings set for
May 6, 2022	EX-10.1	Employment Agreement, dated as of November 24, 2020 among Maravai LifeSciences Holdings, Inc., Cygnus Technologies, LLC, MLSC Holdings, LLC and Christine Dolan. Exhibit 10.1 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement") is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation ("Parent"), Cygnus Technologies, LLC, a Delaware limited liability company ("Employer"), MLSC Holdings, LLC, a Delaware limited liability company (?MLSC?), and Christine Dolan ("Executive"). Capita
May 6, 2022	EX-10.2	Employment Agreement, dated as of November 24, 2020 among Maravai LifeSciences Holdings, LLC, Maravai Intermediate Holdings, LLC and Kurt Oreshack. Exhibit 10.2 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (?Parent?), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (?Employer?), and Kurt Oreshack (?Executive?). Capitalized terms used but not otherwise defined herein shall hav
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (Co
May 5, 2022	EX-99.1	MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Affirms Revenue Guidance and Raises Adjusted EBITDA and Adjusted EPS Guidance Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS Affirms Revenue Guidance and Raises Adjusted EBITDA and Adjusted EPS Guidance SAN DIEGO, Calif., — May 5, 2022 — Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quar
April 14, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 d343471ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commissi
March 1, 2022	EX-21.1	List of subsidiaries of Maravai LifeSciences Holdings, Inc. Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC TriLink Biotechnologies, LLC (Delaware) Glen Research, LLC (Delaware) MockV Solutions, Inc. (Maryland) Cygnus Technologies,
March 1, 2022	EX-4.2	Description of Maravai LifeSciences Holdings, Inc.’s Securities. Exhibit 4.2 Description of Registrant?s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2021, Maravai LifeSciences Holdings, Inc. (the ?Company,? ?we,? ?our,? and ?us?) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the Securities Exchange Act of 1934, as amended. T
March 1, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact
March 1, 2022	EX-2.3	Letter Agreement, dated November 24, 2021, amending the Agreement and Plan of Merger, dated as of August 5, 2021, among Maravai Life Sciences, Inc., Voyager Group Holdings, Inc., Maravai LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC (incorporated by reference to Exhibit 2.3 to Maravai LifeSciences Holdings, Inc.'s Form 10-K filed on March 1, 2022). EXHIBIT 2.3 Voyager Group Holdings, Inc. c/o Thompson Street Capital Partners VI, L.P. 7676 Forsyth Blvd., Suite 2700 Saint Louis, Missouri 63105 November 24, 2021 VIA EMAIL AND COURIER SERVICES Maravai Life Sciences, Inc. 10770 Wateridge Circle Suite 200 San Diego, California 92121 Email: [email protected] Re: Extension of Period to Deliver the Closing Statement Mr. Oreshack: Reference is
February 23, 2022	EX-99.1	MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND UPDATES 2022 FINANCIAL GUIDANCE Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND UPDATES 2022 FINANCIAL GUIDANCE SAN DIEGO, Calif., ? February 23, 2022 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and the full yea
February 23, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio
February 14, 2022	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / D1 Capital Partners L.P. - MARAVAI LIFESCIENCES HOLDINGS, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, $0.01 par value (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
February 14, 2022	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / Select Equity Group, L.P. - SCHEDULE 13G (AMENDMENT NO. 3) Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to whic
February 14, 2022	EX-99.1	EXHIBIT 99.1 EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
February 11, 2022	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / MARAVAI LIFE SCIENCES HOLDINGS 2, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the Appropriate
February 10, 2022	SC 13G/A	MRVI / Maravai LifeSciences Holdings, Inc. Class A / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Maravai LifeSciences Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 56600D107 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which th
February 2, 2022	SC 13G	MRVI / Maravai LifeSciences Holdings, Inc. Class A / MASSACHUSETTS FINANCIAL SERVICES CO /MA/ - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MARAVAI LIFESCIENCES HOLDINGS INC (Name of Issuer) Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w
January 28, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation
January 28, 2022	EX-99.1	Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s Trilink mRNA technologies Increases capabilities serving the high growth cell and gene th Maravai LifeSciences Acquires MyChem, a Leader in Proprietary Ultra-Pure Nucleotides MyChem?s nucleotide synthesis methods are highly complementary to Maravai?s Trilink mRNA technologies Increases capabilities serving the high growth cell and gene therapy market SAN DIEGO, Calif.
January 20, 2022	EX-10.1	Amendment No. 2, dated as of January 19, 2022, to the Credit Agreement, dated as of October 19, 2020, among Maravai Intermediate Holdings, LLC, Cygnus Technologies, LLC, Trilink Biotechnologies, LLC, Maravai Topco Holdings, LLC and Morgan Stanley Senior Funding, Inc. (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings Inc.’s Form 8-K filed on January 20, 2022). SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of January 19, 2022 (this ?Amendment?), amends that certain Credit Agreement, dated as of October 19, 2020 (as amended, restated, amended and restated, supplemented or otherwise modified prior to the Second Amendment Effective Date (as defined below), the ?Credit Agreement?), among Maravai Intermediate Holding
January 20, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2022 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation
January 3, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio
November 15, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, In
November 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio
November 10, 2021	EX-99.1	MARAVAI LIFESCIENCES REPORTS THIRD QUARTER FINANCIAL RESULTS, UPDATES 2021 FINANCIAL GUIDANCE AND PROVIDES PRELIMINARY REVENUE GUIDANCE FOR 2022 Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS THIRD QUARTER FINANCIAL RESULTS, UPDATES 2021 FINANCIAL GUIDANCE AND PROVIDES PRELIMINARY REVENUE GUIDANCE FOR 2022 SAN DIEGO, Calif., ? November 10, 2021 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the thi
November 9, 2021	SC 13G	MRVI / Maravai LifeSciences Holdings, Inc. Class A / Select Equity Group, L.P. - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock (Title of Class of Securities) 56600D107 (CUSIP Number) October 31, 2021 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which
November 9, 2021	EX-99.2	EXHIBIT 99.1 EXHIBIT 99.1 The identity and the Item 3 classification of the relevant subsidiary are: Select Equity Group, L.P., which is an Investment Adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
November 9, 2021	EX-99.2	EXHIBIT 99.2 EXHIBIT 99.2 AGREEMENT OF REPORTING PERSONS The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each
September 13, 2021	424B4	20,000,000 Shares Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-259366 20,000,000 Shares Class A Common Stock The selling stockholders named in this prospectus are offering 20,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders. Our Class A common stock is li
September 7, 2021	CORRESP	MARAVAI LIFESCIENCES HOLDINGS, INC. September 7, 2021 CORRESP 1 filename1.htm MARAVAI LIFESCIENCES HOLDINGS, INC. September 7, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-1090 Attention: Michael Davis Joe McCann Re: Maravai LifeSciences Holdings, Inc. Registration Statement on Form S-1 (File No. 333-259366) Originally Filed September
September 7, 2021	CORRESP	[Signature Page Follows] Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, New York 10022 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 September 7, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-1090 Attention: Michael Davis Joe McCann Re: Ma
September 7, 2021	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 20,000,000 Shares MARAVAI LIFESCIENCES HOLDINGS, INC. CLASS A COMMON STOCK (PAR VALUE $0.01 PER SHARE) UNDERWRITING AGREEMENT September [?], 2021 1 September [?], 2021 Morgan Stanley & Co. LLC Jefferies LLC Goldman Sachs & Co. LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Goldman Sachs & Co. LLC 200 W
September 7, 2021	S-1	As filed with the Securities and Exchange Commission on September 7, 2021 Table of Contents As filed with the Securities and Exchange Commission on September 7, 2021 Registration No.
September 3, 2021	EX-2.1	Amendment No. 1, dated as of September 2, 2021, to the Agreement and Plan of Merger, dated as of August 5, 2021, among Maravai Life Sciences, Inc., Voyager Group Holdings, Inc., Maravai LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER (this ?Amendment?), is made as of September 2, 2021, by and among Maravai Life Sciences, Inc., a Delaware corporation (?Seller?), Voyager Group Holdings, Inc., a Delaware corporation (?Parent?), VYGR Merger Sub, Inc., a Delaware corporation (?Merger Sub?), Maravai LifeSciences Holdings, Inc., a Del
September 3, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporatio
September 3, 2021	EX-10.1	Amendment No. 1, effective as of June 6, 2021, to the Supply Agreement, dated as of October 9, 2020, among TriLink Biotechnologies, LLC, Pfizer Inc. and BioNTech SE. CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED.
August 26, 2021	DRS	Confidential Treatment Requested by Maravai Life Sciences Holdings, Inc. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on August 26, 2021 pursuant to the Jumpstart Our Business Startups Act DRS 1 filename1.htm Table of Contents Confidential Treatment Requested by Maravai Life Sciences Holdings, Inc. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on August 26, 2021 pursuant to the Jumpstart Our Business Startups Act of 2012. This draft registration statement has not been publicly filed with the Securities and Exchange Commiss
August 11, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (E
August 10, 2021	EX-2.1	Agreement and Plan of Merger, dated as of August 5, 2021, among Maravai Life Sciences, Inc., Voyager Group Holdings, Inc., Maravai LifeSciences Holdings, Inc., and Maravai Intermediate Holdings, LLC (incorporated by reference to Exhibit 2.1 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on August 10, 2021). EX-2.1 2 exhibit21to8-10x218xkproje.htm EX-2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among MARAVAI LIFE SCIENCES, INC., as Seller, VOYAGER GROUP HOLDINGS, INC., as Parent, VYGR MERGER SUB, INC., as Merger Sub, and MARAVAI LIFESCIENCES HOLDINGS, INC. and MARAVAI INTERMEDIATE HOLDINGS, LLC, as the Maravai Guarantors, Dated as of August 5, 2021 KE 78589182 TABLE OF CONTENTS ARTICLE I
August 10, 2021	EX-99.1	MARAVAI LIFESCIENCES REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS SECOND QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE SAN DIEGO ? August 10, 2021 ? Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the second quarter ended June 30, 2021, together with other busin
August 10, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation)
May 20, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorporation) (C
May 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (
May 10, 2021	EX-99.1	MARAVAI LIFESCIENCES REPORTS FIRST QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE EX-99.1 2 exhibit991-q12021.htm EX-99.1 Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FIRST QUARTER FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE SAN DIEGO — May 10, 2021 — Maravai LifeSciences Holdings, Inc. (Maravai)(NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March
May 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39725 (Commission F
April 19, 2021	DEF 14A	Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e
April 9, 2021	PRE 14A	- PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e
April 9, 2021	424B4	18,000,000 Shares Class A Common Stock Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-255043 18,000,000 Shares Class A Common Stock The selling stockholders named in this prospectus are offering 18,000,000 shares of our Class A common stock. We are not selling any shares under this prospectus and we will not receive any proceeds from the sale of shares by the selling stockholders. Our Class A common stock is li
April 7, 2021	S-1MEF	- S-1MEF As filed with the Securities and Exchange Commission on April 7, 2021 Registration No.
April 6, 2021	EX-1.1	Form of Underwriting Agreement. Exhibit 1.1 [●] Shares MARAVAI LIFESCIENCES HOLDINGS, INC. CLASS A COMMON STOCK (PAR VALUE $0.01 PER SHARE) UNDERWRITING AGREEMENT April [●], 2021 April [●], 2021 Morgan Stanley & Co. LLC Jefferies LLC Goldman Sachs & Co. LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Goldman Sachs & Co. LLC 200 West Street New Yo
April 6, 2021	S-1/A	- S-1/A As filed with the Securities and Exchange Commission on April 6, 2021 Registration No.
April 5, 2021	CORRESP	- Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, New York 10022 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 April 5, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: Maravai LifeSciences Holdings, Inc. Registration
April 5, 2021	CORRESP	- CORRESP 1 filename1.htm MARAVAI LIFESCIENCES HOLDINGS, INC. April 5, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-1090 Attention: Abby Adams Re: Maravai LifeSciences Holdings, Inc. Registration Statement on Form S-1 (File No. 333-255043) Originally Filed April 5, 2021 CIK: 0001823239 Ladies and Gentlemen: Maravai LifeSciences Holdings, I
April 5, 2021	S-1	Registration Statement - S-1 Table of Contents As filed with the Securities and Exchange Commission on April 5, 2021 Registration No.
April 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39725 (Commission
April 5, 2021	EX-99.1	MARAVAI LIFESCIENCES ANNOUNCES PRELIMINARY UNAUDITED FIRST QUARTER REVENUES AND INCOME FROM OPERATIONS RANGE Exhibit 99.1 MARAVAI LIFESCIENCES ANNOUNCES PRELIMINARY UNAUDITED FIRST QUARTER REVENUES AND INCOME FROM OPERATIONS RANGE SAN DIEGO—Maravai LifeSciences Holdings, Inc. (Maravai or the Company)(NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today provided preliminary unaudited revenue and Income from Operations estimates for the quarter
March 25, 2021	DRS	Confidential Treatment Requested by Maravai LifeSciences Holdings, Inc. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on March 24, 2021 pursuant to the Jumpstart Our Business Startups Act o DRS 1 filename1.htm Table of Contents Confidential Treatment Requested by Maravai LifeSciences Holdings, Inc. Pursuant to 17 C.F.R. Section 200.83 As submitted confidentially to the Securities and Exchange Commission on March 24, 2021 pursuant to the Jumpstart Our Business Startups Act of 2012. This draft registration statement has not been publicly filed with the Securities and Exchange Commissio
March 22, 2021	EX-21.1	List of subsidiaries of Maravai LifeSciences Holdings, Inc. (incorporated by reference to Exhibit 21.1 to Maravai LifeSciences Holdings, Inc.’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 22, 2021). Exhibit 21.1 Subsidiaries of the Registrant Subsidiaries of Maravai LifeSciences Holdings, Inc. Maravai Topco Holdings, LLC (Delaware) Subsidiaries of Maravai Topco Holdings, LLC Maravai Intermediate Holdings, LLC (Delaware) Subsidiaries of Maravai Intermediate Holdings, LLC TriLink Biotechnologies, LLC (Delaware) Glen Research, LLC (Delaware) Vector Laboratories, Inc. (California) MockV Solutions
March 22, 2021	EX-4.2	Description of Maravai LifeSciences Holdings, Inc.’s Securities. EX-4.2 2 mrvi-20orm10xkxex42xdescri.htm EX-4.2 Exhibit 4.2 Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities and Exchange Act of 1934. General As of December 31, 2020, Maravai LifeSciences Holdings, Inc. (the “Company,” “we,” “our,” and “us”) had one class of securities, our Class A common stock, par value $0.01 per share, registered under Section 12 of the
March 22, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-39725 Maravai LifeSciences Holdings, Inc. (Exact
March 2, 2021	EX-99.1	MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND INITIATES 2021 FINANCIAL GUIDANCE EX-99.1 2 exhibit991.htm EX-99.1 Exhibit 99.1 MARAVAI LIFESCIENCES REPORTS FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND INITIATES 2021 FINANCIAL GUIDANCE SAN DIEGO—Maravai LifeSciences Holdings, Inc. (Maravai)(NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and the full
March 2, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-39725 (Commission
February 16, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.001 per share (Title of Class of Securities) 56600D107 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
February 11, 2021	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Tit SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Maravai LifeSciences Holdings, Inc. (Name of Issuer) Class A Common Stock, par value $0.01 per share (Title of Class of Securities) 56600D 107 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the approp
February 11, 2021	EX-99.A	AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G EX-99.A Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Class A common stock of Maravai LifeSciences Holding Corp. may be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G. Date: February 11, 2021 MARAVAI LIFE SCIENCES
February 10, 2021	SC 13G	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Maravai LifeSciences Holdings Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 56600D107 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed
November 25, 2020	EX-4.1	Registration Rights Agreement, dated November 24, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 4.1 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020). EX-4.1 Exhibit 4.1 MARAVAI LIFESCIENCES HOLDINGS, INC. REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made as of November 24, 2020 among Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), each of the investors listed on the signature pages hereto under the caption “Sponsor Investors” (collectively, the “Sponsor Investors”), and each
November 25, 2020	EX-3.1	Amended and Restated Certificate of Incorporation of Maravai LifeSciences Holdings, Inc. dated November 19, 2020 (incorporated by reference to Exhibit 3.1 to Maravai Life Sciences Holdings, Inc.’s Form 8-K filed on November 25, 2020) EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MARAVAI LIFESCIENCES HOLDINGS, INC. * * * * * Carl Hull, being the Chief Executive Officer of Maravai LifeSciences Holdings, Inc., a corporation duly organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY as follows: FIRST: The present name of
November 25, 2020	EX-10.1	Tax Receivable Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020). Exhibit 10.1 EXECUTION VERSION TAX RECEIVABLE AGREEMENT BY AND AMONG MARAVAI LIFESCIENCES HOLDINGS, INC., CERTAIN OTHER PERSONS NAMED HEREIN, AND THE AGENT DATED AS OF NOVEMBER 19, 2020 TABLE OF CONTENTS Page RECITALS 1 ARTICLE I DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Other Definitional and Interpretative Provisions 10 ARTICLE II DETERMINATION OF CERTAIN REALIZED TAX BENEFITS 10 Secti
November 25, 2020	EX-1.1	Underwriting Agreement, dated as of November 19, 2020, among Maravai LifeSciences Holdings, Inc., Maravai Topco Holdings, LLC and Morgan Stanley & Co. LLC, Jefferies LLC and Goldman Sachs & Co. LLC, as representatives for the underwriters named therein. EX-1.1 Exhibit 1.1 60,000,000 Shares MARAVAI LIFESCIENCES HOLDINGS, INC. CLASS A COMMON STOCK (PAR VALUE $0.01 PER SHARE) UNDERWRITING AGREEMENT November 19, 2020 1 November 19, 2020 Morgan Stanley & Co. LLC Jefferies LLC Goldman Sachs & Co. LLC c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Goldman Sachs & Co. LLC 20
November 25, 2020	EX-10.5	Director Nomination Agreement, dated as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 10.5 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020). EX-10.5 Exhibit 10.5 DIRECTOR NOMINATION AGREEMENT THIS DIRECTOR NOMINATION AGREEMENT (this “Agreement”) is made and entered into as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), Maravai Life Sciences Holdings, LLC, a Delaware limited liability company (“MLSH 1”), Maravai Life Sciences Holdings 2, LLC, a Delaware limited liability c
November 25, 2020	EX-10.8	Employment Agreement of Carl W. Hull, dated November 24, 2020, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Carl W. Hull (incorporated by reference to Exhibit 10.8 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020). EX-10.8 Exhibit 10.8 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Carl W. Hull (“Executive”). Capitalized terms used but not otherwise defined herein sh
November 25, 2020	EX-99.1	Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares EX-99.1 Exhibit 99.1 Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares SAN DIEGO, Calif. - November 24, 2020 - Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public
November 25, 2020	EX-10.9	Employment Agreement of Kevin Herde, dated November 24, 2020, among Maravai LifeSciences Holdings, Inc., Maravai Intermediate Holdings, LLC and Kevin Herde (incorporated by reference to Exhibit 10.9 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020). EX-10.9 11 d31788dex109.htm EX-10.9 Exhibit 10.9 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), Maravai Intermediate Holdings, LLC, a Delaware limited liability company (“Employer”), and Kevin Herde (“Executive”). Capitalized terms used but not
November 25, 2020	EX-10.3	Second Amended and Restated Limited Liability Agreement of Maravai Topco Holdings, LLC, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 10.3 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020). EX-10.3 Exhibit 10.3 EXECUTION VERSION MARAVAI TOPCO HOLDINGS, LLC SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of November 19, 2020 THE UNITS ISSUED PURSUANT TO THIS SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE S
November 25, 2020	EX-10.10	Employment Agreement of Brian Neel, dated November 24, 2020, among Maravai LifeSciences Holdings, Inc., TriLink Biotechnologies, LLC and Brian Neel (incorporated by reference to Exhibit 10.10 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020). EX-10.10 Exhibit 10.10 EXECUTION VERSION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made as of November 24, 2020, by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (“Parent”), TriLink Biotechnologies, LLC, a Delaware limited liability company (“Employer”), and Brian Neel (“Executive”). Capitalized terms used but not otherwise defined herein shall ha
November 25, 2020	EX-10.2	Exchange Agreement, dated as of November 19, 2020, by and among Maravai LifeSciences Holdings, Inc. and the other signatories party thereto (incorporated by reference to Exhibit 10.2 to Maravai LifeSciences Holdings, Inc.’s Form 8-K filed on November 25, 2020). Exhibit 10.2 EXECUTION VERSION EXCHANGE AGREEMENT This EXCHANGE AGREEMENT (as it may be amended from time to time in accordance with the terms hereof, this “Agreement”), dated as of November 19, 2020 and effective as of immediately prior to the consummation of the IPO (as defined below) (the “Effective Time”), is made by and among Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “C
November 25, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events - 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2020 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39725 85-2786970 (State or other jurisdiction of incorpor
November 25, 2020	EX-3.2	Amended and Restated Bylaws of Maravai LifeSciences Holdings, Inc. dated November 19, 2020 (incorporated by reference to Exhibit 3.2 to Maravai Life Sciences Holdings, Inc.’s Form 8-K filed on November 25, 2020). EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MARAVAI LIFESCIENCES HOLDINGS, INC. A Delaware corporation (Adopted as of November 19, 2020) ARTICLE I OFFICES Section 1. Offices. Maravai LifeSciences Holdings, Inc. (the “Corporation”) may have an office or offices other than its registered office at such place or places, either within or outside the State of Delaware, as the Board of Directors o
November 23, 2020	EX-10.2	Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.2 to Maravai LifeSciences Holdings, Inc.’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on November 23, 2020). EX-10.2 Exhibit 10.2 Final Version MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I PURPOSE The Maravai LifeSciences Holdings, Inc. 2020 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) is intended to assist Eligible Employees of Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), and its Designate
November 23, 2020	EX-10.1	Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to Maravai LifeSciences Holdings, Inc.’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on November 23, 2020). EX-10.1 Exhibit 10.1 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN ARTICLE I PURPOSE The purpose of this Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan is to promote the success of the Company’s business for the benefit of its stockholders by enabling the Company to offer Eligible Individuals cash and stock-based incentives in order to attract, retain, and reward
November 23, 2020	424B4	60,000,000 Shares Class A Common Stock 424B4 Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-249733 60,000,000 Shares Class A Common Stock This is the initial public offering of shares of Class A common stock of Maravai LifeSciences Holdings, Inc., par value $0.01 per share. Maravai LifeSciences Holdings, Inc. is offering 60,000,000 shares of its Class A common stock to be sold in the offering. Prior to this off
November 23, 2020	S-8	- S-8 S-8 As filed with the Securities and Exchange Commission on November 23, 2020 Registration No.
November 19, 2020	8-A12B	Form 8-A 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Maravai LifeSciences Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 85-2786970 (I.R.S. Employer Identification
November 19, 2020	S-1MEF	- S-1MEF S-1MEF As filed with the Securities and Exchange Commission on November 19, 2020 No.
November 16, 2020	CORRESP	- CORRESP Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 Jefferies LLC 520 Madison Avenue New York, New York 10022 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 November 16, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christine Torney Lynn Dicker Laura Crotty Suzanne Ha
November 16, 2020	CORRESP	- CORRESP MARAVAI LIFESCIENCES HOLDINGS, INC. November 16, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-1090 Attention: Christine Torney Lynn Dicker Laura Crotty Suzanne Hayes Re: Maravai LifeSciences Holdings, Inc. Registration Statement on Form S-1 Originally Filed October 29, 2020 File No. 333-249733 Ladi
November 13, 2020	EX-99.10	Consent of Anat Ashkenazi EX-99.10 Exhibit 99.10 The undersigned hereby consents to being named in the registration statement on Form S-1 and in all subsequent amendments and post-effective amendments or supplements thereto and in any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Registration Statement”) of Maravai
November 13, 2020	EX-10.7	Form of Stock Option Grant Notice and Stock Option Agreement (incorporated by reference to Exhibit 10.7 to Amendment No. 2 to Maravai LifeSciences Holdings, Inc.’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 13, 2020). EX-10.7 Exhibit 10.7 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN STOCK OPTION GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Participant”)
November 13, 2020	EX-10.27	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement (incorporated by reference to Exhibit 10.27 to Amendment No. 2 to Maravai LifeSciences Holdings, Inc.’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 13, 2020). EX-10.27 Exhibit 10.27 MARAVAI LIFESCIENCES HOLDINGS, INC. 2020 OMNIBUS INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Pursuant to the terms and conditions of the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan, as amended from time to time (the “Plan”), Maravai LifeSciences Holdings, Inc., a Delaware corporation (the “Company”), hereby grants to the individual listed below (“Pa
November 13, 2020	S-1/A	- S-1/A S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 13, 2020 No.
November 9, 2020	EX-3.2	Form of Amended and Restated Bylaws of Maravai LifeSciences Holdings, Inc. (incorporated by reference to Exhibit 3.2 to Amendment No. 1 to the Registrant’s Registration Statement on Form S-1 (No. 333-249733), filed with the Commission on November 9, 2020) EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MARAVAI LIFESCIENCES HOLDINGS, INC. A Delaware corporation (Adopted as of [•], 20[•]) ARTICLE I OFFICES Section 1. Offices. Maravai LifeSciences Holdings, Inc. (the “Corporation”) may have an office or offices other than its registered office at such place or places, either within or outside the State of Delaware, as the Board of Directors of the C
November 9, 2020	S-1/A	- S-1/A S-1/A As filed with the Securities and Exchange Commission on November 9, 2020 No.
November 9, 2020	EX-10.10	Form of Second Amended and Restated Limited Liability Agreement of Maravai Topco Holdings, LLC EX-10.10 Exhibit 10.10 MARAVAI TOPCO HOLDINGS, LLC SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT Dated as of [•], 2020 THE UNITS ISSUED PURSUANT TO THIS SECOND AMENDED AND RESTATED LIMITED LIABILITY COMPANY AGREEMENT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR UNDER ANY OTHER APPLICABLE SECURITIES LAWS. SUCH UNITS MAY NOT BE SOLD, TRANSFERRED, ASSIGN

MRVI / Maravai LifeSciences Holdings, Inc. - SEC-arkiveringer, Årsrapport, Fullmaktsdokument

Grunnleggende statistikk

SEC Filings

SEC Filings (Chronological Order)

Other Listings

MX:MRVI
DE:MAR	€ 2,28